CDK12 INHIBITION REVERSES DE NOVO AND ACQUIRED PARP INHIBITOR RESISTANCE IN BRCA WILD-TYPE AND MUTATED MODELS OF TRIPLE-NEGATIVE BREAST CANCER

Although poly (ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired resistance following restoration of HR. Here, we report that dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5 and 9, addition...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Rep
Main Authors: Johnson, Shawn F., Cruz, Cristina, Greifenberg, Ann Katrin, Dust, Sofia, Stover, Daniel G., Chi, David, Primack, Benjamin, Cao, Shiliang, Bernhardy, Andrea J., Coulson, Rhiannon, Lazaro, Jean-Bernard, Kachupurakkal, Bose, Sun, Heather, Unitt, Christine, Moreau, Lisa A., Sarosiek, Kristopher A., Scaltriti, Maurizio, Juric, Dejan, Baselga, José, Richardson, Andrea L., Rodig, Scott J., D’Andrea, Alan D., Balmaña, Judith, Johnson, Neil, Geyer, Matthias, Serra, Violeta, Lim, Elgene, Shapiro, Geoffrey I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5176643/
https://ncbi.nlm.nih.gov/pubmed/27880910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2016.10.077
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados